Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway

Enhancing tumor immunotherapy with smart nanoparticles for reprogramming macrophages and blocking the CD47/Sirpα pathway

Immunotherapy has significantly advanced cancer treatment, but the tumor immune microenvironment (TIME) often remains immunosuppressive, limiting therapeutic efficacy. Tumor-associated macrophages (TAMs), particularly M2-like macrophages, play a crucial role in promoting tumor growth and immune evas...

Full description

Saved in:
Bibliographic Details
Main Authors: Zubair Hussain, Shanshan Gou, Xu Liu, Mengyu Li, Hanyue Zhang, Sumei Ren, Ruxia Han, Fangfang Liu, Xiaowen Zhou, Lu Qiu, Hongfei Wang, Zhenzhen Chen, Kangdong Liu
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Materials Today Bio
Subjects:
Tumor immunotherapy
Tumor-associated macrophage
STING agonist
CD47/Sirpα axis
Smart PMM-Expressing cell membrane
Online Access:http://www.sciencedirect.com/science/article/pii/S2590006425003862
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy has significantly advanced cancer treatment, but the tumor immune microenvironment (TIME) often remains immunosuppressive, limiting therapeutic efficacy. Tumor-associated macrophages (TAMs), particularly M2-like macrophages, play a crucial role in promoting tumor growth and immune evasion. Our study introduces a novel approach using dual-targeted ZrMOF/C@P nanoparticles, smartly engineered with cell membrane coating and enzyme responsiveness, to effectively modulate TAMs. These nanoparticles are synthesized and loaded with 2′, 3′-cGAMP, a STING agonist, and encapsulated in a peptide-expressed macrophage membrane (PMM) featuring Pep20, MMP2, and M2pep. In vitro, they activate the STING pathway in M2-like macrophages and reprogram them into M1-like macrophages. Smart ZrMOF/C@P is found to accumulate at the tumor even 72 h post-injection. In CT26 and 4T1 tumor models show that smart ZrMOF/C@P not only suppresses tumor growth but also stimulates systemic immune responses. This is evidenced by a reduction in M2-like and an increase in M1-like macrophages, enhanced dendritic cell (DC) maturation, and increased tumor infiltration of CD4+ and CD8+ T cells, accompanied by elevated IFN-γ secretion. This innovative use of ZrMOF/C@P offers a promising strategy to transform the immunosuppressive TIME, presenting a versatile and effective treatment option for solid tumors, and novel avenue for non-CDN-STING agonists, facilitating systemic administration.
ISSN:2590-0064

Similar Items